Beam Therapeutics Valuation
| BEAM Stock | USD 27.92 0.30 1.09% |
At this time, the firm appears to be fairly valued. Beam Therapeutics shows a prevailing Real Value of $27.96 per share. The current price of the firm is $27.92. Our model approximates the value of Beam Therapeutics from analyzing the firm fundamentals such as return on equity of -0.47, and Operating Margin of (13.08) % as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Beam Therapeutics' valuation include:
Price Book 2.9014 | Enterprise Value | Enterprise Value Ebitda (7.03) | Price Sales 50.3176 | Enterprise Value Revenue 33.7371 |
Fairly Valued
Today
Please note that Beam Therapeutics' price fluctuation is not too volatile at this time. Calculation of the real value of Beam Therapeutics is based on 3 months time horizon. Increasing Beam Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Beam stock is determined by what a typical buyer is willing to pay for full or partial control of Beam Therapeutics. Since Beam Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Beam Stock. However, Beam Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 27.92 | Real 27.96 | Target 47.21 | Hype 27.92 | Naive 24.11 |
The intrinsic value of Beam Therapeutics' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Beam Therapeutics' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Beam Therapeutics helps investors to forecast how Beam stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Beam Therapeutics more accurately as focusing exclusively on Beam Therapeutics' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Beam Therapeutics' intrinsic value based on its ongoing forecasts of Beam Therapeutics' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Beam Therapeutics' closest peers.
Beam Therapeutics Cash |
|
Beam Therapeutics Total Value Analysis
Beam Therapeutics is currently forecasted to have valuation of 2.05 B with market capitalization of 2.8 B, debt of 161.43 M, and cash on hands of 1.09 B. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Beam Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
2.05 B | 2.8 B | 161.43 M | 1.09 B |
Beam Therapeutics Investor Information
About 99.0% of the company shares are held by institutions such as insurance companies. The book value of Beam Therapeutics was currently reported as 9.8. The company recorded a loss per share of 4.41. Beam Therapeutics last dividend was issued on the February 4, 2014. The entity had 2:1 split on the October 26, 1990. Based on the key indicators related to Beam Therapeutics' liquidity, profitability, solvency, and operating efficiency, Beam Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in March.Beam Therapeutics Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Beam Therapeutics has an asset utilization ratio of 5.75 percent. This suggests that the Company is making $0.0575 for each dollar of assets. An increasing asset utilization means that Beam Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Beam Therapeutics Profitability Analysis
Based on Beam Therapeutics' profitability indicators, Beam Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Beam Therapeutics' ability to earn profits and add value for shareholders.Net Loss | First Reported 2018-03-31 | Previous Quarter -102.3 M | Current Value -112.7 M | Quarterly Volatility 56.8 M |
For Beam Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Beam Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Beam Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Beam Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Beam Therapeutics over time as well as its relative position and ranking within its peers.
Beam Therapeutics Earnings per Share Projection vs Actual
The next projected EPS of Beam Therapeutics is estimated to be -1.1504 with future projections ranging from a low of -1.354225 to a high of -0.8825. Beam Therapeutics' most recent 12-month trailing earnings per share (EPS TTM) is at -4.41. Please be aware that the consensus of earnings estimates for Beam Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Beam Therapeutics Earnings Estimation Breakdown
The calculation of Beam Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Beam Therapeutics is estimated to be -1.1504 with the future projection ranging from a low of -1.354225 to a high of -0.8825. Please be aware that this consensus of annual earnings estimates for Beam Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.35 Lowest | Expected EPS | -0.88 Highest |
Beam Therapeutics Earnings Projection Consensus
Suppose the current estimates of Beam Therapeutics' value are higher than the current market price of the Beam Therapeutics stock. In this case, investors may conclude that Beam Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Beam Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2026 | Current EPS (TTM) | |
| 16 | 67.31% | 0.0 | -1.1504 | -4.41 |
Beam Therapeutics Ownership Allocation
The majority of Beam Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Beam Therapeutics to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Beam Therapeutics. Please pay attention to any change in the institutional holdings of Beam Therapeutics as this could imply that something significant has changed or is about to change at the company.Beam Therapeutics Profitability Analysis
The company reported the previous year's revenue of 63.52 M. Net Loss for the year was (376.74 M) with loss before overhead, payroll, taxes, and interest of (356.09 M).About Beam Therapeutics Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Beam Therapeutics. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Beam Therapeutics based exclusively on its fundamental and basic technical indicators. By analyzing Beam Therapeutics's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Beam Therapeutics's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Beam Therapeutics. We calculate exposure to Beam Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Beam Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -273.6 M | -260 M | |
| Pretax Profit Margin | (5.34) | (5.60) | |
| Operating Profit Margin | (5.89) | (6.18) | |
| Net Loss | (5.34) | (5.61) | |
| Gross Profit Margin | (4.31) | (4.52) |
Beam Therapeutics Current Valuation Indicators
Beam Therapeutics' valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Beam Therapeutics' valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Beam Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Beam Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Beam Therapeutics' worth.When determining whether Beam Therapeutics is a strong investment it is important to analyze Beam Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Beam Therapeutics' future performance. For an informed investment choice regarding Beam Stock, refer to the following important reports: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Beam Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Beam Stock, please use our How to Invest in Beam Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Will Biotechnology sector continue expanding? Could Beam diversify its offerings? Factors like these will boost the valuation of Beam Therapeutics. Projected growth potential of Beam fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Beam Therapeutics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (4.41) | Revenue Per Share | Quarterly Revenue Growth (0.32) | Return On Assets | Return On Equity |
The market value of Beam Therapeutics is measured differently than its book value, which is the value of Beam that is recorded on the company's balance sheet. Investors also form their own opinion of Beam Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Beam Therapeutics' true underlying value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Because Beam Therapeutics' market value can be influenced by many factors that don't directly affect Beam Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between Beam Therapeutics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Beam Therapeutics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, Beam Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.